<DOC>
	<DOCNO>NCT00895960</DOCNO>
	<brief_summary>Phase I : Primary Objectives : -To define maximum tolerate dose ( MTD ) dasatinib ( Sprycel ) radiotherapy ( RT ) 6 week concomitant temozolomide ( TMZ ) administer 75 mg/m^2/day patient newly-diagnosed glioblastoma ( GBM ) . Secondary Objectives : - To characterize safety profile dasatinib ( Sprycel ) combination radiotherapy ( RT ) concomitant TMZ patient newly-diagnosed GBM . - To characterize safety profile dasatinib ( Sprycel ) combination adjuvant TMZ patient glioblastoma RT . STUDY DID NOT PROGRESS TO PHASE II PORTION . Phase II : Primary Objectives : -To determine effectiveness dasatinib ( Sprycel ) radiotherapy ( RT ) 6 week concomitant temozolomide ( TMZ ) administer 75 mg/m^2/day follow adjuvant temozolomide concurrent dasatinib patient newly-diagnosed glioblastoma ( GBM ) measure overall survival . Secondary Objectives : - To determine efficacy treatment measure radiographic response ( RR ) , progression-free survival ( PFS ) time progression ( TTP ) . - To characterize safety profile dasatinib ( Sprycel ) combination RT concomitant TMZ patient newly-diagnosed GBM . - To characterize safety profile dasatinib ( Sprycel ) combination adjuvant TMZ patient GBM RT . Exploratory Objectives : -To correlate tumor genotype , tumor expression dasatinib target protein ( e.g . Src , EphA2 , c-kit PDGFR ) , PTEN level response therapy dasatinib temozolomide .</brief_summary>
	<brief_title>Dasatinib Plus Radiation Therapy/Temozolomide Newly-Diagnosed Glioblastoma</brief_title>
	<detailed_description>PHASE I The Study Drugs : Dasatinib design change function certain gene . By change function gene , may prevent cancer grow spread . It also design block low activity one tumor-causing proteins responsible uncontrolled growth tumor cell , may result shrink stop tumor growth . Temozolomide design kill cancer cell damage DNA ( genetic material cell ) . The damage DNA may cause tumor cell death . Study Groups : If find eligible take part study , assign dose level dasatinib base join study . Up 2 dose level dasatinib test . Three ( 3 ) participant enrol dose level . The first group participant receive low dose level . Each new group receive high dose group , intolerable side effect see . This continue high tolerable dose dasatinib give combination temozolomide find . All group take dose level temozolomide entire study . The amount study drug receive may change experience side effect . If time experience intolerable side effect , tell study doctor right away . Study Drug Administration : During Radiation : As part standard care , receive radiation therapy Monday-Friday total 30 radiation treatment ( 6 week ) . Every day receive radiation , take temozolomide mouth day maximum 7 week . You swallow temozolomide whole , one right , without chew . If vomit take temozolomide , take capsule next schedule dose . They take empty stomach ( least 1 hour 2 hour eat ) 1 cup ( 8 oz . ) water . Every day receive radiation , take dasatinib mouth 1 time day maximum 7 week . You take dasatinib without food ( 1 hour 2 hour eat ) , least 1 cup ( 8 oz . ) water . After Radiation : After radiation therapy end , every day , continually take dasatinib mouth 1 time day . You take temozolomide 4 week radiation therapy end . After 4 week , begin take temozolomide 1 time day , mouth , Days 1-5 28 day study cycle . Study Visits : Four ( 4 ) week end radiation , every 4 week , follow test procedure perform : - You physical exam , include measurement vital sign . - You neurological exam . - You performance status evaluation . - You ask drug may take experienced side effect . - Blood ( 1 teaspoon ) drawn check blood 's ability clot normally . Every week first 6 week , every 4 week , ask experienced side effect . If take anti-seizure drug , every 2 week first 6 week every 4 week , blood ( 1 teaspoon ) drawn check level anti-seizure drug blood . At Week 6 , cycle radiation first 6 cycle , ECG . Every week first 6 week , Days 1 22 every cycle radiation , blood ( 3 teaspoon ) collect routine test . Four ( 4 ) week end radiation , every 8 week , MRI scan check status disease . Length Study : You may continue take temozolomide 12 cycle . You may continue take dasatinib long benefit . You take study early disease get bad experience intolerable side effect . End-of-Study Visit : After go study , end-of-study visit . At visit , follow test procedure perform : - Your complete medical history record . - You physical exam . - You performance status evaluation . - You ask drug may take experienced side effect . - You neurological exam . - Blood ( 3 1/2 teaspoon ) collect routine test check blood 's ability clot normally . - If take anti-seizure drug , blood ( 1 teaspoon ) drawn check level anti-seizure drug blood . Long-Term Follow-up visit : After end-of-study visit , study team/staff contact telephone every 3 month check . Each phone call take 5 minute . This investigational study . Temozolomide FDA approve commercially available treatment brain tumor . Dasatinib FDA approve commercially available treatment type leukemia , experimental use brain tumor . In addition , combination temozolomide dasatinib experimental use brain tumor . At time , combination use research . Up 72 participant take part study . Up 72 enrol M. D. Anderson .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Central Nervous System Diseases</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>1 . Patients newly diagnose histologically proven intracranial supratentorial GBM gliosarcoma ( GS ) eligible protocol . Patients eligible original histology grade II III glioma subsequent histological diagnosis GBM make . 2 . All patient must sign informed consent indicate aware investigational nature study . 3 . Diagnosis establish biopsy resection 1428 day prior registration . In order permit healing , patient receive Day 1 treatment least 14 day surgery . 4 . Patients must prior cranial RT 5 . Patients must plan begin partial brain RT day first dasatinib dose first dose TMZ . Radiotherapy perform either MD Anderson outside facility . Radiotherapy must give external beam partial brain field daily fraction 180 200 cGy , plan total dose tumor approximately 6000 cGy . Stereotactic radiosurgery brachytherapy allow . 6 . Patients must receive prior cytotoxic drug therapy , noncytotoxic drug therapy , experimental drug therapy brain tumor . 7 . Patients must &gt; /= 18 year old . 8 . A contrast enhance brain scan perform within 14 day prior registration corticosteroid dose stable decrease least 5 day . If corticosteroid dose increase date imaging registration , new baseline MRI/CT require . The type scan , i.e. , MRI CT , must use throughout period protocol treatment tumor measurement . The use MRI rather CT prefer . 9 . Patients must Karnofsky performance status &gt; /= 60 . 10 . Patients must adequate bone marrow function ( WBC &gt; /= 3,000/Âµl , ANC &gt; /= 1,500/mm^3 , platelet count &gt; /= 100,000/mm^3 , hemoglobin &gt; /= 10 gm/dl ) , adequate liver function ( SGOT , SPGT bilirubin &lt; /= 2 time ULN ) , serum Na , K+ , Mg^2+ , phosphate Ca^2+ &gt; /= Lower Limit Normal ( LLN ) adequate renal function ( creatinine &lt; /= 1.5 mg/dL creatinine clearance &gt; /= 60 cc/min/1.73 m^2 ) start therapy . These test must perform within 14 day prior registration . Eligibility level hemoglobin may reach transfusion . 11 . Patients must willing forego cytotoxic noncytotoxic drug therapy tumor enrol study . 12 . Women childbearing potential must negative betaHCG pregnancy test document within 14 day prior registration . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . 1 . Patients must receive prior Gliadel wafer . 2 . Patients must receive investigational agent within 30 day prior commence study treatment . 3 . Patients must significant medical illness investigator 's opinion adequately control appropriate therapy would compromise patient 's ability tolerate therapy . 4 . Patients history cancer ( except nonmelanoma skin cancer carcinoma situ cervix ) , unless complete remission therapy disease minimum 3 year ineligible . 5 . Uncontrolled intercurrent illness include , limited , ongoing active infection psychiatric illness/social situation would limit compliance study requirement . 6 . Patients follow invasive procedure : ) Major surgical procedure , open biopsy significant traumatic injury &lt; 14 day prior Day 1 therapy b ) Anticipation need major surgical procedure course study c ) Core biopsy within 7 day prior Day 1 therapy . 7 . Patients must pregnant/breastfeeding must agree practice adequate contraception . Breastfeeding discontinue mother treat dasatinib . 8 . Patients clinically significant cardiovascular disease : ) History ischemic hemorrhagic stroke within past 6 month b ) Uncontrolled hypertension , define blood pressure &gt; 140/90 mm Hg systolic BP &gt; 180 mm Hg diastolic blood pressure &lt; 90 mm Hg , least 2 repeated determination separate day within past 3 month c ) Myocardial infarction , CABG unstable angina within past 6 month ) New York Heart Association grade III great congestive heart failure , serious cardiac arrhythmia require medication , unstable angina pectoris within past 6 month 9 . ( 8. continue ) e ) Clinically significant peripheral vascular disease within past 6 month f ) Pulmonary embolism , DVT , thromboembolic event within past 6 month . g ) Diagnosed congenital long QT syndrome h ) Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsades de pointes ) ) Prolonged QTc interval preentry electrocardiogram ( &gt; 450 msec ) j ) Subjects hypokalemia hypomagnesemia correct prior dasatinib administration 10 . Evidence bleed diathesis coagulopathy INR &gt; 1.5 . History significant bleeding disorder unrelated cancer , include : ) Diagnosed congenital bleeding disorder ( e.g. , von Willebrand 's disease ) b ) Diagnosed acquire bleed disorder within one year ( e.g. , acquire antifactor VIII antibody ) c ) Ongoing recent ( &lt; /= 3 month ) significant gastrointestinal bleeding 11 . Patients know HIV ineligible study . 12 . Patients must disease obscure toxicity dangerously alter drug metabolism . 13 . Patients must receive prior therapy dasatinib indication . 14 . Inclusion Women Minorities : Both men woman member race ethnic group eligible trial . 15 . Patients follow medication exclude : ) Anticonvulsants : Patients Enzyme Inducing Anticonvulsants ( EIAED ) exclude . If patient previously EIAEDs discontinue , patient must EIAEDs &gt; /= 2 week prior initiation dasatinib . It also note whether patient previously receive EIAEDs last date administration EIAEDs . 16 . ( 15. continue ) b ) Antacids : Use H2 blocker proton pump inhibitor prohibit systemic antacid ( H2 inhibitor , proton pump inhibitor ) decrease dasatinib absorption . Patients require antacid use short acting , locally active agent ( e.g. , Maalox , Mylanta etc. ) . However , agent take within either 2 hour 2 hour dasatinib dose . This particularly important patient glioblastoma frequently dexamethasone prophylactic H2 blocker proton pump inhibitor . 17 . ( 15. continue ) c ) Anticoagulants/Antiplatelets : Patients therapeutic ( treatment ) dose anticoagulant ( e.g . warfarin , low molecularweight heparin ) eligible . Patients allow take aspirin , clopidogrel , ticlopidine , Aggrenox . Patients prophylactic anticoagulation may enrol treat study long platelet count monitor closely maintain &gt; 75,000 receive Dasatinib . 18 . ( 15. continue ) ) Ibuprofen NSAIDS : Ibuprofen nonsteroidal antiinflammatory drug ( NSAIDS ) inhibit platelet function . Patients may take ibuprofen NSAIDs study entry must stop agent &gt; /=7 day prior start dasatinib allow appropriate washout period . 19 . ( 15. continue ) e ) Inducers Inhibitors CYP3A4 : Patients require drug exclude ( exception Dexamethasone , effort make reduce dose dexamethasone ) . Patients may discontinue drug least 7 day prior start dasatinib . 20 . ( 15. continue ) f ) Category I drug generally accept risk cause Torsades de Pointes include : ( Patients must discontinue drug least 7 day prior start dasatinib ) ( 1 ) . quinidine , procainamide , disopyramide ( 2 ) . amiodarone , sotalol , ibutilide , dofetilide ( 3 ) . erythromycin , clarithromycin ( 4 ) . chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide ( 5 ) . cisapride , bepridil , droperidol , methadone , arsenic , chloroquine , domperidone , halofantrine , levomethadyl , pentamidine , sparfloxacin , lidoflazine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Brain</keyword>
	<keyword>CNS Disease</keyword>
	<keyword>CNS</keyword>
	<keyword>Intracranial Supratentorial GBM</keyword>
	<keyword>Gliosarcoma</keyword>
	<keyword>GS</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>GBM</keyword>
	<keyword>Dasatinib</keyword>
	<keyword>Sprycel</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>TMZ</keyword>
	<keyword>Temodar</keyword>
	<keyword>Radiation Therapy</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>RT</keyword>
</DOC>